The place of cladribine in the treatment of chronic lymphocytic leukemia: A 10-year experience in Poland

Annals of Hematology

Volumn 84, Issue 2, 2005, Pages 63-70

  Robak, Tadeusz ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

2 CdA; Cladribine; CLL; Combined treatment; Efficacy; Purine analogs; Randomized study; Richter's syndrome; Secondary cancer; Toxicity

Indexed keywords

ALKYLATING AGENT; CHLORAMBUCIL; CLADRIBINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; MITOXANTRONE; PREDNISONE; RITUXIMAB; VINCRISTINE;

AGE DISTRIBUTION; ANEMIA; AUTOIMMUNE HEMOLYTIC ANEMIA; B CELL LEUKEMIA; B CELL LYMPHOMA; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; DRUG ACTIVITY; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INDUCED CANCER; DRUG POTENTIATION; DRUG RESPONSE; DRUG SAFETY; EOSINOPHILIA; HODGKIN DISEASE; HUMAN; INFECTION; LARGE CELL LYMPHOMA; LEUKEMIA RELAPSE; LUNG CANCER; LYMPHOPROLIFERATIVE DISEASE; MINIMAL RESIDUAL DISEASE; NEUTROPENIA; NONHODGKIN LYMPHOMA; POLAND; PRIORITY JOURNAL; PURE RED CELL ANEMIA; REVIEW; RICHTER SYNDROME; SECOND CANCER; THROMBOCYTOPENIA; WESTERN HEMISPHERE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CLADRIBINE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC; NEOPLASMS, SECOND PRIMARY; POLAND; RANDOMIZED CONTROLLED TRIALS;

EID: 11844305611     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-004-0974-4     Document Type: Review

References (46)

1. Betticher DC, Ratschiller D, Hsu Schmitz SF, von Rohr A, Hess U, Zulian G. (1998) Reduced dose of subcutaneous cladribine induces identical response rates but decreased toxicity in pretreated chronic lymphocytic leukaemia. Swiss Group for Clinical Cancer Research (SAKK). Ann Oncol 9:721-726 10.1023/A:1008273131598
2. Chasty RC, Myint H, Oscier DG, Orchard JA, Bussutil DP, Hamon MD, Prentice AG, Cooplestone J (1998) Autoimmune haemolysis in patients with B-CLL treated with chlorodeoxyadenosine (CDA). Leuk Lymphoma 29:391-398 1:CAS:528:DC%2BD3cXisFOhu7w%3D
3. Cheson BD, Vena DA, Barrett J, Freidlin B (1999) Second malignancies as a consequence of nucleoside analog therapy for chronic lymphoid leukemias. J Clin Oncol 17:2454-2460 1:CAS:528:DyaK1MXltlylt7c%3D
4. Fridrik MA, Jager G, Kienzer HR, Hausmaninger H, Oppitz P, Krieger O, Zabernigg A, Lang A, Neubaur M, Weidinger G, Schiller L, Seewann HL, Chott A, Linkesch W (1998) Efficacy and toxicity of 2-chlorodeoxyadenosine 2-h infusion for 5 days as first-line treatment for advanced low grade non-Hodgkin's lymphoma. Eur J Cancer 34:1560-1564 10.1016/S0959-8049(98)00140-3
5. Góra-Tybor J, Robak T (1993) Synergistic action of 2-chlorodeoxyadenosine and cyclophosphamide on murine leukemias L1210 and P388. Acta Haematol Pol 24:177-182 8103959
6. Juliusson G, Liliemark J (1992) Rapid recovery from cytopenia in hairy cell leukemia after treatment with 2-chloro-2′deoxyadenosine (CdA): Relation to opportunistic infections. Blood 79:888-894 1:STN:280:By2C2cvpvFQ%3D
7. Karisson K, Stromberg M, Liliemark J, Delannoy A, Johnson SA, Porwit A et al (2000) Oral cladribine for B-cell chronic lymphocytic leukaemia: report of a phase II trial with a 3-d, 3-weekly schedule in untreated and pretreated patients and a long-term follow-up of 126 previously untreated patients. Br J Haematol 116:538-548 10.1046/j.0007-1048.2001.03296.x
8. Keating MJ, O'Brien S, Kantarjian H, Plunkett W, Estey E, Koller C, Beran M, Freireich EJ (1993) Long-term follow-up of patients with chronic lymphocytic leukaemia treated with fludarabine as a single agent. Blood 81:2878-2884 1:STN:280:ByyB2s7kslU%3D
9. Keating MJ, O'Brien S, Lerner S, Koller C, Beran M, Robertson LE, Freireich EJ, Estey E, Kantarjian H (1998) Long-term follow-up of patients with chronic lymphocytic leukaemia (CLL) receiving fludarabine regimens as initial therapy. Blood 92:1165-1171 1:CAS:528:DyaK1cXlsVWrsLc%3D
10. Krykowski E, Warzocha K, Robak T (1995) 2-chlorodeoxyadenosine (2-CdA) in the treatment of patients with relapsed chronic lymphocytic leukemia. Arch Immunol Ther Exp 43:317-321 1:STN:280:BymA38jpvFU%3D
11. Liliemark J, Juliusson G (1991) On the pharmacokinetics of 2-chloro-2′-deoxyadenosine in humans. Cancer Res 51:70-72
12. Montillo M, Tedeschi A, O'Brien S, Di Raimondo F, Lerner S, Ferajoli A, Morra E, Keating MJ (2003) Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia. Cancer 97:114-120 10.1002/cncr.11000
13. O'Brien SM, Kantarjian HH, Cortes J, Beran M, Koller C, Giles FI, Lerner S, Keating M (2001) Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol 19:1414-1420 1:CAS:528:DC%2BD3MXit1ertLw%3D
14. Piro LD, Carrera CJ, Beutler E, Carson DA (1988) 2-Chlorodeoxyadenosine: an effective new agent for the treatment of chronic lymphocytic leukemia. Blood 72:1069-1073 1:STN:280:BieA38jhtFE%3D
15. Pocock C, Matutes E, Wotherspoon A, Cunnigham D, Catovsky D (1998) Fludarabine therapy may precipitate large cell transformation in chronic lymphocytic leukaemia but not in follicular lymphoma (abstract 1774). Blood 92 [Suppl 1]:429a
16. Robak T (2001) Cladribine in the treatment of chronic lymphocytic leukaemia. Leuk Lymphoma 40:551-564 1:CAS:528:DC%2BD3MXjtVCjtbY%3D
17. Robak T, Błasińska-Morawiec M, Krykowski E, Hellmann A, Konopka L (1997) Autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia. Eur J Haematol 58:109-113 1:CAS:528:DyaK2sXislGitbc%3D
18. Robak T, Błasińska-Morawiec M, Błoński JZ., Dmoszyńska A (1999) 2-Chlorodeoxyadenosine (cladribine) in the treatment of elderly patients with B-cell chronic lymphocytic leukemia. Leuk Lymphoma 34:151-157 1:CAS:528:DC%2BD3cXlsFSksL8%3D
19. Robak T, Błasińska-Morawiec M, Błoński JZ, Krykowski E, Komarnicki M, Trepińska E, Kazimierczuk M, Hansz J, Dmoszyńska A, Roliński J, Konopka L, Skotnicki AB, Nowak WS, Kotlarek-Haus S, Zdziarska B, Urasiński I (1997) The effect of 2-h infusion of 2-chlorodeoxyadenosine (cladribine) with prednisone in previously untreated B-cell chronic lymphocytic leukemia. Eur J Cancer 33:2347-2351 10.1016/S0959-8049(97)00349-3
20. Robak T, Błasińska-Morawiec M, Krykowski E, Hellmann A, Lewandowski K, Dmoszyńśka A, Adamczyk-Cioch M, Kazimierczak M, Trepińska E, Dwilewicz-Trojaczek M, Kuratowska Z, Skotnicki AB, Nowak WS, Zdziarska B, Urasiński I (1997) 2-Chlorodeoxyadenosine (cladribine)-related eosinophilia in patients with lymphoproliferative diseases. Eur J Haematol 59:216-220 1:CAS:528:DyaK2sXms12mtLs%3D
21. Robak T, Błasińska-Morawiec M, Krykowski E, Kasznicki M, Płuzańska A, Petoemski P, Hellmann A, Zaucha JM, Lewandowski K, Dmoszyńska A, Hansz J, Komarnicki M, Konopka L, Durzyński T, Ceglarek B, Sikorska A, Kotlarek-Haus S, Mazur G, Urasiński I, Zdziarska B, Maj S, Kopeć I, Skotnicki AB, Dwilewicz-Trojaczek J, Kuratowska Z, Grieb P (1996) Intermittent 2-hour intravenous infusions of 2-chlorodeoxyadenosine in the treatment 110 patients with refractory or previously untreated B-cell chronic lymphocytic leukemia. Leuk Lymphoma 22:509-514 1:STN:280:ByiD3sjjtFw%3D
22. Robak T, Błasińska-Morawiec M, Krykowski E., Hansz J, Komarnicki M, Kazimierczak M, Konopka L, Maj S, Hellmann A, Zaucha JM, Urasiński I, Zdziarska B, Kotlarek-Haus S, Usnarska-Zubkiewicz L, Kuratowska Z, Dwilewicz-Trojaczek J, Hołowiecki J, Krawczyk-Kuliś M, Grieb P (1996) 2-chlorodeoxyadenosine (2-CdA) in 2-hour versus 24-hour intravenous infusion in the treatment of patients with hairy cell leukemia. Leuk Lymphoma 22:107-111 1:STN:280:BymA3s%2FptF0%3D
23. Robak T, Błasińśka-Morawiec M, Krykowski E (1992) Transient eosinophilia in a patient with hairy cell leukaemia treated with 2-chlorodeoxyadenosine. Acta Haematol Pol 23:285-290 1:STN:280:ByyC1M%2Fnt1A%3D
24. Robak T, Błoński JZ, Kasznicki M, Błasińska-Morawiec M, Krykowski E, Dmoszyńska A, Mrugała-Śpiewak H, Skotnicki AB, Nowak W, Konopka L, Ceglarek B, Maj S, Dwilewicz-Trojaczek J, Hellmann A, Urasiński I, Zdziarska B, Kotlarek-Haus S, Potoczek S, Grieb P (2000) Cladribine with prednisone versus chlorambucil with prednisone as first-line therapy in chronic lymphocytic leukemia: Report of a prospective randomized, multicenter trial. Blood 96:2723-2729 1:CAS:528:DC%2BD3cXnt12gsb0%3D
25. Robak T, Bloński JZ, Góra-Tybor J, Kasznicki M, Konopka L, Ceglarek B, Komarnicki M, Lewandowski K, Hellmann A, Lewandowski K, Moskwa A, Dmoszyńśka A, Sokołowska B, Dwilewicz-Trojaczek A, Tomaszewska A, Sułek K, Całbecka M (2004) Second malignancies and Richter's syndrome in patients with chronic lymphocytic leukaemia treated with cladribine. Eur J Cancer 40:383-389 10.1016/j.ejca.2003.09.031
26. Robak T, Błoński JZ, Kasznicki M, Góra-Tybor J, Dwilewicz-Trojaczek J, Stella-Hołowiecka B, Wołowiec D (2002) Cladribine combined with cyclophosphamide is highly effective in the treatment of chronic lymphocytic leukemia. Hematol J 3:244-250 10.1038/sj.thj.6200191
27. Robak T, Błoński JZ, Kasznicki M, Góra-Tybor J, Dwilewicz-Trojaczek J, Boguradzki P, Konopka L, Ceglarek B, Sułek J, Kuliczkowski K, Wołowiec D, Stella-Hołowiecka B, Skotnicki AB, Nowak W, Moskwa-Sroka B, Dmoszyńska A, Całbecka M (2001) Cladribine combined with mitoxantrone and cyclophosphamide as front-line therapy in chronic lymphocytic leukemia. Leukemia 15:1510-1516 10.1038/sj.leu.2402216
28. Robak T, Błoński JZ, Kasznicki M, Góra-Tybor J, Dwilewicz-Trojaczek J, Tomaszewska A, Konopka L, Ceglarek B, Dmoszyńśka A, Kowal M, Całbecka M, Zawilska K, Stella-Hołowiecka B, Sułek K, Gawroński K, Kuliczkowski K, Potoczek S, Kłoczko J, Jeromin J, Warzocha K (2003) Comparison of cladribine alone and in combination with cyclophosphamide or cyclophosphamide and mitoxantrone in previously untreated B-CLL patients: An updated report of a randomized study (abstract 78). Leuk Lymphoma 44 [Suppl 2]:S44
29. Robak T, Błoński JZ, Kasznicki M, Góra-Tybor J, Hellmann A, Konopka L, Dmoszyńśka A, Dwilewicz-Trojaczek J, Wołowiec D (2002) Re-treatment with cladribine-based regimens in relapsed patients with B-cell chronic lymphocytic leukemia. Efficacy and toxicity in comparison with previous treatment. Eur J Haematol 69:27-36 10.1034/j.1600-0609.2002.02711.x
30. Robak T, Błoński JZ, Kasznicki M, Konopka L, Ceglarek B, Dmoszyńska A, Soroka-Wojtaszko M, Skotnicki AB, Nowak W, Dwilewicz-Trojaczek J, Tomaszewska A, Hellmann A, Lewandowski K, Kuliczkowski K, Potoczek S, Zdziarska B, Hansz J, Kroll R, Komarnicki M, Hołowiecki J, Grieb P (2000) Cladribine with or without prednisone in the treatment of previously treated and untreated B-cell chronic lymphocytic leukemia-updated results of the multicentre study of 378 patients. Br J Haematol 108:357-368 10.1046/j.1365-2141.2000.01850.x
31. Robak T, Błoński JZ, Urbańska-Ryś H, Błasińska-Morawiec M, Skotnicki AB (1999) 2-chlorodeoxyadenosine (Cladribine) in the treatment of patients with chronic lymphocytic leukemia 55 years old and younger. Leukemia 13:518-523 10.1038/sj/leu/2401368
32. Robak T, Góra-Tybor J, Lech-Marańda E, Błoński JZ, Kasznicki M (2001) Cladribine in combination with mitoxantrone and cyclophosphamide (CMC) in the treatment of heavily pre-treated patients with advanced indolent lymphoid malignancies. Eur J Haematol 66:188-194 10.1034/j.1600-0609.2001.00303.x
33. Robak T, Kasznicki M, Bartkowiak J, Kordek R, Wawrzyniak E, Błoński JZ (2001) Richter's syndrome following cladribine therapy for chronic lymphocytic leukemia first manifested as pathologic fracture of the femur. Leuk Lymphoma 42:789-796 1:STN:280:DC%2BD3MnksVKhsg%3D%3D
34. Robak T, Kasznicki M, Błońśki JZ, Dmoszyńska A, Skotnicki AB (2001) Pure red cell aplasia in patients with chronic lymphocytic leukaemia treated with cladribine. Br J Haematol 112:1083-1085 10.1046/j.1365-2141.2001.02622-2.x
35. Robak T, Kasznicki M (2002) Alkylating agents and nucleoside analogues in the treatment of B-cell chronic lymphocytic leukemia. Leukemia 16:1015-1027 10.1038/sj.leu.2402531
36. Robak T, Smolewski P, Urbańśka-Ryś H, Góra-Tybor J, Błoński JZ, Kasznicki M (2004) Rituximab followed by cladribine in the treatment of heavily pretreated patients with indolent lymphoid malignancies. Leuk Lymphoma 45:937-944 10.1080/1042819032000159825
37. Robak T, Szmigielska-Kapłon A, Smolewski P, Wawrzyniak E, Korycka A, Bartkowiak J, Kordek R (2003) Hodgkin's type of Richter's syndrome in familial chronic lymphocytic leukemia treated with cladribine and cyclophosphamide. Leuk Lymphoma 44:859-866 10.1080/1042819031000063417
38. Robak T, Urbańśka-Ryś H, Strzelecka B, Krykowski E, Bartkowiak J, Błoński JZ, Kordek R, Warzocha K (2001) Plasmablastic lymphoma in a patient with chronic lymphocytic leukemia heavily pretreated with cladribine (2-CdA): An unusual variant of Richter's syndrome. Eur J Haematol 67:322-327 10.1034/j.1600-0609.2001.00592.x
39. Saven A, Carrera CJ, Carson DA, Beutler E, Piro LD (1991) 2-Chlorodeoxyadenosine treatment of refractory chronic lymphocytic leukaemia. Leuk Lymphoma 16 [Suppl 5]:133-138
40. Saven A, Piro LD (1993) 2-Chlorodeoxyadenosine in the treatment of hairy cell leukemia. Cancer Invest 11:559-564 1:STN:280:ByuD3crnvVU%3D
41. Seymour JF, Kurzrock R, Freireich EJ, Estey EH (1994) 2-Chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with hairy cell leukemia. Blood 83:2906-2911 1:CAS:528:DyaK2cXlt1Cksrk%3D
42. Smolewski P, Szmigielska A, Cebula B, Sobczak A, Darzynkiewicz Z, Robak T (2002) Pro-apoptotic effect of rituximab alone and in combination with purine nucleoside analogues in B-CLL chronic lymphocytic leukemia cells measured by fluorochrome labeled inhibitors of caspases (FLICA) assay (abstract 1503). Blood 100 [Suppl 1]:387a
43. Szmigielska-Kapłon A, Ciesielska E, Szmigiero L, Robak T (2002) Anthracyclines potentiate activity against murine leukemias L1210 and P388 in vivo and in vitro. Eur J Haematol 68:370-375 10.1034/j.1600-0609.2002.01598.x
44. Tallman MS, Hakimian D (1995) Purine nucleoside analogs: Emerging roles in indolent lymphoproliferative disorders. Blood 86:2463-2474 1:CAS:528:DyaK2MXot1Ohurk%3D
45. van Den Neste E, Bontemps F, Delacauw A, Cardoen S, Louviaux I, Scheiff JM, Gills E, Leveugle P, Deneys L, Ferrant A, Van den Gerghe G (1999) Potentiation of antitumor effects of cyclophosphamide derivatives in B-chronic lymphocytic leukemia cells by 2-chloro-2′deoxyadenosine. Leukemia 13:918-925 10.1038/sj/leu/2401431
46. van Den Neste E, Louviaux I, Michaux JL, Delannoy A, Michaux L, Hagemeijer A, Scheiff JM, Bosly A, Straetmans N, Ferrant A (1999) Myelodysplastic syndrome with monosomy 5 and/or 7 following therapy with 2-chloro-2′-deoxyadenosine. Br J Haematol 105:268-270 10.1046/j.1365-2141.1999.01277.x